Gunnar Gislason As the dust continues to settle on the Vioxx issue, there is naturally a desire to look further at potential cardiovascular risks associated with COX-2 inhibitors and, indeed, other no
Gunnar Gislason
As the dust continues to settle on the Vioxx issue, there is naturally a desire to look further at potential cardiovascular risks associated with COX-2 inhibitors and, indeed, other non-steroidal anti-inflammatories.Gunnar Gislasonfrom Bispebjerg University Hospital has been leading a study aiming to look throughout Denmark for a relationship between the use of these drugs and mortality in people who have had a myocardial infarction.